Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Dissociable hindbrain GLP1R circuits for satiety and aversion
Kuei-Pin Huang, Alisha A Acosta, Misgana Y. Ghidewon, et al.
Nature (2024) Vol. 632, Iss. 8025, pp. 585-593
Closed Access | Times Cited: 30
Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Wafa Ali Aldhaleei, Tadesse Melaku Abegaz, Akshaya Srikanth Bhagavathula
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 199-199
Open Access | Times Cited: 19
Obesity management: sex-specific considerations
Tobias Kantowski, Clarissa Schulze zur Wiesch, Jens Aberle, et al.
Archives of Gynecology and Obstetrics (2024) Vol. 309, Iss. 5, pp. 1745-1752
Open Access | Times Cited: 18
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 34
Case Report: Semaglutide-associated depression: a report of two cases
Jiarui Li, Jinya Cao, Jing Wei, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 25
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
Yamin Shu, Jing Chen, Yiling Ding, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
Cătălin Vlăduț Ionuț Feier, Razvan Constantin Vonica, Alaviana Monique Faur, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4346-4346
Open Access | Times Cited: 14
Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 12
Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety
Cheng Jiang, Jiancheng Qian, Xin Jiang, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 10
A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Zhiwei Cui, Feiyan Cheng, Lihui Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Yiming Qi, Jing Li, Sisi Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment
Yamin Shu, Lei Wang, Yiling Ding, et al.
Drug Safety (2023) Vol. 46, Iss. 9, pp. 881-895
Closed Access | Times Cited: 13
Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database
Xiang Li, Shi‐Nan Wu, Si-Qi Zhang, et al.
Expert Opinion on Drug Safety (2025), pp. 1-9
Open Access
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
Weidong Zhang, Yunzhou Chen, Zeyu Yao, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 114-114
Open Access
Cardiovascular toxicities of hypoxia-inducible factor prolyl hydroxylase inhibitors: a disproportionality analysis based on JADER database
Danna Wu, Ting Xie, Shuxin Jiao, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
Lingling Wang, Zhenyu Mao, Pengdou Zheng, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database
Fang Wu, Siliang Wang, Xihui Xu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Celestine I. Odigwe, Rajasekhar Mulyala, H. A. Malik, et al.
American Heart Journal Plus Cardiology Research and Practice (2025) Vol. 52, pp. 100518-100518
Open Access
Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database
Jinhua Liu, Liping Xue, Fanxiang Zeng, et al.
European Child & Adolescent Psychiatry (2025)
Closed Access
Exogenous oral application of PYY and exendin-4 impacts upon taste-related behavior and taste perception in wild-type mice
Sivaraman Iyer, Jean‐Pierre Montmayeur, Sergei Zolotukhin, et al.
Neuropharmacology (2025), pp. 110408-110408
Closed Access
Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system
Chengyu Zhu, Zhiwei Cui, Tingting Liu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database
Peng Xie, Lishan Lu, Yixuan Tian, et al.
SAGE Open Medicine (2025) Vol. 13
Open Access
Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database
Jinlong Huang, Miaomiao Zhang, Jingyang Lin, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP‐1RA‐based weight‐loss therapies
Reimar W. Thomsen, Aurélie Mailhac, Julie B. Løhde, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Page 1 - Next Page

Scroll to top